Multi-dimensional Prevention Program After Acute Coronary Syndrome (ELIPS) (SPUM-ACS- SP1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01075867|
Recruitment Status : Unknown
Verified January 2014 by François MACH, University Hospital, Geneva.
Recruitment status was: Recruiting
First Posted : February 25, 2010
Last Update Posted : March 18, 2014
Information provided by (Responsible Party):
François MACH, University Hospital, Geneva
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||December 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Weidmann L, Obeid S, Mach F, Shahin M, Yousif N, Denegri A, Muller O, Räber L, Matter CM, Lüscher TF. Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes. Int J Cardiol. 2019 Jan 15;275:171-178. doi: 10.1016/j.ijcard.2018.10.050. Epub 2018 Oct 16.